Nuformix PLC AGM Results (8767L)

TIDMNFX

RNS Number : 8767L

Nuformix PLC

10 September 2019

10th September 2019

Nuformix plc

("Nuformix" or "the Group"),

Result of Annual General Meeting

The Annual General Meeting of Nuformix plc was held on 10(th) September 2019 at 1.00pm, at the offices of Shakespeare Martineau LLP, 60 Gracechurch Street, London, EC3V 0HR.

As announced this morning resolution 7 was withdrawn from the meeting. The Directors of the Company wish to announce that all other resolutions put to shareholders were duly passed and approved on a show of hands at the meeting. The results of the proxy voting position received in advance of the meeting are reported below:

 
                  Resolution               Ordinary/       For               Against          Total votes 
                                            Special                                               cast 
                                                         No. of        %     No. of     % 
                                                          votes               votes 
      To receive the annual 
       report and accounts 
       for the year ended 
 1     31 March 2019                       Ordinary    121,471,999    100       0       0     121,471,999 
      To approve the Annual 
 2     Report on Remuneration              Ordinary    121,413,979    100       0       0     121,413,979 
      To re-appoint David 
 3     Tapolczay as a director             Ordinary    121,465,547    100       0       0     121,465,547 
      To re-appoint Daniel 
 4     Gooding as a director               Ordinary    121,471,999    100       0       0     121,471,999 
      To re-appoint Joanne 
 5     Holland as a director               Ordinary    121,465,547    100       0       0     121,465,547 
      To re-appoint John 
 6     Lidgey as a director                Ordinary    83,841,906    99.85   123,641   0.15   83,965,547 
 7    To re-appoint Kirk                   Ordinary    Withdrawn 
       Siderman-Wolter 
       as a director 
      To re-Christopher 
 8     Blackwell as a director             Ordinary    121,465,547    100       0       0     121,465,547 
      To re-appoint haysmacintyre 
 9     as auditor                          Ordinary    121,465,547    100       0       0     121,465,547 
                 To authorise the 
                  Directors to determine 
 10               the auditor's fees.      Ordinary    121,465,547    100       0       0     121,465,547 
      To authorise the 
       Directors to allot 
 11    shares.                             Ordinary    121,471,999    100       0       0     121,471,999 
                 To authorise the 
                  Directors to disapply 
 12               pre-emption rights.       Special    121,465,547    100       0       0     121,465,547 
                 To authorise the 
                  Company to purchase 
 13               its own shares.           Special    121,471,999    100       0       0     121,471,999 
          To authorise calling 
           of a general meeting 
           on 14 clear days' 
 14        notice.                          Special    121,471,999    100       0       0     121,471,999 
 

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 469,466,512 ordinary shares of GBP0.001 each. Copies of the resolutions passed as special resolutions at the AGM will shortly be available for inspection at the National Storage Mechanism, which is located at: http://www.morningstar.co.uk/uk/nsm.

Enquiries:

 
 Nuformix plc 
  Dr Dan Gooding, Chief Executive 
  Officer                             [phone] 
 Optimum Strategic Communications 
  Mary Clark, Supriya Mathur             [phone] 
  Email: [e-mail]                  9144 
 

About Nuformix plc: www.nuformix.com

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGLLFSEADIILIA

(END) Dow Jones Newswires

September 10, 2019 11:49 ET (15:49 GMT)